It is noteworthy that because of the various effects of JNK in cell physiology, JNK inhibitors can not be a selective therapeutic choice; however, using novel drug delivery systems and/or design of selective inhibitors conjugated to etoposide could be useful in cancer therapy. The gene discussed is MAPK8; the disease is cancer.